Geron Corp. (GERN) Drops 11.83% on January 19

Equities Staff |

Geron Corp. (GERN) was one of the Russell 2000's biggest losers for Tuesday January 19 as the stock slid 11.83% to $2.95, a loss of $-0.395 per share. Starting at an opening price of $3.38 a share, the stock traded between $2.93 and $3.43 over the course of the trading day. Volume was 3.2 million shares over 10,463 trades, against an average daily volume of 2.97 million shares and a total float of 158.22 million.

The losses send Geron Corp. down to a market cap of $465.96 million. In the last year, Geron Corp. has traded between $5.30 and $2.60, and its 50-day SMA is currently $4.35 and 200-day SMA is $3.87.

Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.

Geron Corp. is based out of Menlo Park, CA and has some 42 employees. Its CEO is John A. Scarlett.

For a complete fundamental analysis analysis of Geron Corp., check out’s Stock Valuation Analysis report for GERN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Breathtec BioMedical Inc.

Breathtec Biomedical Inc is a medical diagnostics company. It is engaged in developing & commercializing breath analysis devices for the early detection of infections & life threatening diseases including cancers,…

Private Markets


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…